Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer

  • The European Commission (EC) has approved Ipsen SA's (OTC:IPSEY) Cabometyx (cabozantinib) as monotherapy in differentiated thyroid carcinoma (DTC) setting.
  • The approval covers adult patients with locally advanced or metastatic DTC, refractory or not eligible for radioactive iodine, who have progressed during or after systemic therapy. 
  • This EC approval follows the FDA approval announced by Exelixis Inc (NASDAQ:EXEL) in September 2021 of Cabometyx for adult and pediatric patients with locally advanced or metastatic DTC.
  • The approval was based on results from the COSMIC-311 Phase 3 trial, which at a planned interim analysis, demonstrated a significant reduction in the risk of disease progression or death by 78% versus placebo.
  • The objective response rate also favored Cabometyx with 15% vs. 0% for placebo (p=0.028) but did not meet the criteria for statistical significance.
  • At a median follow-up of 10.1 months, the final results demonstrated Cabometyx's median PFS of 11.0 months versus 1.9 months with placebo and a maintained reduction in disease progression or death risk of 78% versus placebo.
  • Price Action: EXEL shares closed 1.43% higher at $22.66 on Monday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.